Results of exogenous GDF11 supplementation – the view of Patient Zero

Steve Perry

CEO, GDF11Rejuvenation.com

Results of exogenous GDF11 supplementation in over 100 human volunteers – the view of Patient Zero

Longevity.Technology: One of the most popular speaker sessions at Longevity 2020 was from Steve Perry who shared his experience as the first of 200+ patients who have experimented with GDF11.

GDF11 has recently emerged as a promising anti-aging agent. The naturally occurring molecule GDF11 is crucial for stem cell DNA repair. During aging, stem cells accumulate DNA damage, leading to stem cell senescence, the main characteristics of which is the decline in stem cell quantity and function. Exogenous GDF11 can boost the regenerative potential of the body, and thereby reverse aging and improve the symptoms of age-related conditions.

Was Dexter the dog a cancer survivor? You can find out in this short and compelling video from Steve:

 

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...